Myriad Genetics Submits First Module of the Premarket Approval Application to FDA for the myChoice® HRD CDx Test April 9, 2019 Myriad Genetics Submits First Module of the Premarket Approval Application to FDA for the myChoice® HRD CDx Test myChoice HRD Is Intended to Identify Patients ... Continue Reading
Myriad, AstraZeneca and Merck Expand Companion Diagnostic Partnership April 4, 2019 Myriad, AstraZeneca and Merck Expand Companion Diagnostic Partnership BRACAnalysis CDx® Test Will Be Used to Identify Germline BRCA Mutations in Men with Metas... Continue Reading
Myriad’s BRACAnalysis CDx® Test Successfully Identified Patients with Metastatic Pancreatic Cancer Who Benefitted from Treatment with Olaparib February 26, 2019 Myriad’s BRACAnalysis CDx® Test Successfully Identified Patients with Metastatic Pancreatic Cancer Who Benefitted from Treatment with Olaparib Myriad Will Se... Continue Reading
BRACAnalysis CDx® Approved by U.S. Food and Drug Administration as Companion Diagnostic for AstraZeneca’s Lynparza® (olaparib) in Patients with Advanced-Stage, BRCA-Mutated Ovarian Cancer December 19, 2018 BRACAnalysis CDx® Approved by U.S. Food and Drug Administration as Companion Diagnostic for AstraZeneca’s Lynparza® (olaparib) in Patients with Advanced-Sta... Continue Reading
EndoPredict® Test Receives Positive NICE Recommendation for Patients with Early Breast Cancer December 19, 2018 EndoPredict® Test Receives Positive NICE Recommendation for Patients with Early Breast Cancer NICE Decision is a Major Milestone in Expanding Access to Patient... Continue Reading
Prospective Study Demonstrates EndoPredict® Can Guide Chemotherapy Decision For Women with Early-Stage Breast Cancer December 7, 2018 Prospective Study Demonstrates EndoPredict® Can Guide Chemotherapy Decision For Women with Early-Stage Breast Cancer SALT LAKE CITY, Dec. 07, 2018 (GLOBE NEWS... Continue Reading
Myriad Announces Important New Data for Its EndoPredict® Breast Cancer Test Will Be Presented at the 2018 San Antonio Breast Cancer Symposium December 7, 2018 EndoPredict is the Only Test to Answer Three Critical Questions: Risk of Breast Cancer Recurrence, Benefits of Chemotherapy and Who Can Forgo Extended Endocrine... Continue Reading